The increase in approved AAV based gene therapies in just the last two years along with the over 100 clinical trials currently ongoing () demonstrates that investigation into these gene therapies is continuously progressing. Monitoring AAV vector quality is crucial for ensuring product safety and efficacy. A key aspect of this is monitoring changes in post-translational modifications (PTMs) on the capsid VPs. PTMs on said VPs are known to occur during production and storage and can have an influence on product stability, infectivity, and transduction efficiency . They also are seen varying between production lots highlighting the importance of batch-to-batch monitoring . Additionally, final product yields for full AAV capsids are low due to the high levels of empty or partially filled capsids that are generated during production and need to be removed downstream . Therefore, having highly sensitive AAV characterization platforms is critical to minimize the amount of sample needed for quality control (QC) testing.